Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma
(CP), plasma collected from individuals who have recovered from an infectious disease, has …

During the COVID-19 pandemic, immunoglobulins (IG) have been suggested both as an
immunosuppressive treatment in late COVID-19 stages and as an antiviral in pre-exposure …

COVID-19 convalescent plasma (CCP) has been explored as one of the treatment options
for COVID-19. Results of many cohort studies and clinical trials have been recently …

Objectives The aim of this trial is to investigate the safety and clinical efficacy of passive
immunization therapy through Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C …

In the absence of effective antiviral chemotherapy and still in the context of emerging
vaccines for severe acute respiratory syndrome-CoV-2 infections, passive immunotherapy …

Passive immunotherapy has been used since the late 19th century, and in 1901, the first
Nobel Prize in Physiology or Medicine was awarded for serum therapy for patients with …

The epidemic of corona virus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome Coronavirus 2 and its variants of concern (VOCs) has been ongoing for over 3 …

Passive immunotherapies have been used to treat severe respiratory infections for over a
century, with convalescent blood products from recovered individuals given to patients with …

In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged,
causing a global pandemic called COVID-19. Currently, there is no definitive treatment for …

For over a century, transfusion of convalescent plasma from recovered individuals has been
tried as a therapeutic approach when a novel pathogen emerges. As the world awaits SARS …